Abstract: Objective：To explore the expression and clinical significance of G protein-coupled receptor 30（GPR30） during carcinogenesis of endometrium. Methods：The expression of GPR30 and EGFR in 20 cases of endometrial atypical hyperplasia （EAH group） and 50 cases of endometrial carcinoma （EAC group） were detected by immunohistochemical EliVision two stages method. Another 20 cases of normal endometrial tissue specimen were as a control group. Results：In group of control， EAH group and EAC group， the positive rates of GPR30 were 10.0%，45.0% and 74.0%，respectively. The differences among the three groups was statistically significant（P＜0.001），EAH group was significantly higher than the control group（P＜0.05）， and significantly lower than the EAC group（P＜0.05）. In EAC patients， the expression of GPR30 was not associated with age，surgery-pathological stage， depth of myometrial invasion， tumor size and lymph node metastasis（P＞0.05，respectively） but
the type of histology，the expression of GPR30 with different tumor grade showed a significant statistical difference（P＜0.05）.
The expression rates of EGFR in normal endometrium，EAH and EAC tissues were 30.0%， 40.0% and 70.0%， respectively， showing a rising trend. The positive expression rate and expression intensity of EGFR in EAC group was significantly higher than that in EAH group or control group （P＜0.05，P＜0.001， respectively），but the difference of that between EAH group and control group were no statistical significance（P＞0.05）. In the EAC group， EGFR positive expression intensity correlated with FIGO stage， histopathological grade or tumor diameter （P＜0.05，respectively），its expression did not correlate with any other clinicopathological parameters（P＞0.05）. Positively correlation between the expression of GPR30 and that of EGFR was
observed in EAC group （r=0.308，P＜0.05） Conclusions：GPR30 and EGFR probably have relationships with the occurrence and development of endometrial carcinoma. GPR30 and EGFR expression in endometrial adenocarcinoma was positively
correlated with each other， there could be interaction between the two. GPR30 and EGFR could be more effective novel
therapeutic targets of endometrial cancer.

Key words: Endometrial neoplasms, Adenocarcinoma, Receptor, epidermal growth factor, Prognosis, Immunohistochemistry, G protein-coupled estrogen receptor